Providing market intelligence for more than 35 years

In The News

Roku Bolsters Its Strongest Business With a $150 Million Acquisition

The bears once believed Roku's hardware business would be crushed by rivals like Alphabet's Google Chromecast, Amazon's (NASDAQ:AMZN) Fire TV, and Apple TV. Yet Roku consistently remains the most popular streaming device maker in the U.S., according to Parks Associates' latest numbers.

Between the first quarters of 2017 and 2019, Roku's domestic share of streaming devices rose from 37% to 39%, while its closest rival, Amazon, grew its share from 24% to 30%. However, the gross margin of Roku's player business also plunged from 22.2% to 5.5% between the second quarters of 2018 and 2019 as it sold cheaper devices to maintain that lead. It expects that figure to remain in the low single-digits for the rest of the year.

From the article "Roku Bolsters Its Strongest Business With a $150 Million Acquisition" by Leo Sun.

Previously In The News

Over Two-Thirds Of U.S. Smartphone Owners Stream Music Daily

A recent Parks Associates report reveals that 68 percent of U.S. smartphone owners listen to streaming music every day, for an average of 45 minutes per day. Amazon Prime Music emerged as the most pop...

The future of mobile payments – are there too many options that are confusing consumers and merchants?

“Merchants are still slowly upgrading their retail point of sale (POS) systems to support various mobile payment options while new payment options keep showing up. No merchants have provided a complet...

TV Everywhere Usage Grows

A recent article in Multichannel News provided new findings from Parks Associates showing that 40 percent of U.S. pay TV subscribers used TV Everywhere options in 2015, up from 22 percent in 2013. "TV...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...